$MIRM insider trading
Over the last 12 months, Mirum Pharmaceuticals insiders reported 1 buy totaling $9.0M and 46 sales totaling $42.0M across SEC Form 4 filings. 55% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $9.0M 1 event
- Sold · 12m
- $42.0M 46 events
- Events · 12m
- 47 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 55% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 9,943 | $98.37 | $978K | -18.2% | — |
| Sep 2, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 658 | $100 | $66K | -51.6% | plan |
| Sep 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 30,000 | $98.68 | $3.0M | -13.4% | plan · 2 tranches |
| Aug 18, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 40,000 | $100 | $4.0M | -96.9% | — |
| Aug 11, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 6,001 | $99.9 | $600K | -14.2% | plan |
| Aug 10, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 20,000 | $98.92 | $2.0M | -9.3% | plan · 3 tranches |
| Aug 3, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 1,840 | $105.29 | $194K | -59.1% | plan |
| Jul 6, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 20,000 | $122.27 | $2.4M | -9.3% | plan · 4 tranches |
| Jul 6, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 5,000 | $122.25 | $611K | -10.6% | plan · 4 tranches |
| Jul 1, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 2,721 | $120 | $327K | -46.6% | plan |
| Jun 17, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 2,594 | $101.95 | $264K | -30.8% | plan |
| Jun 8, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 5,000 | $93.82 | $469K | -10% | plan · 3 tranches |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 883 | $99.66 | $88K | -0.5% | plan |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 1,021 | $98.2 | $100K | -0.5% | plan |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 1,973 | $97.56 | $192K | -1% | plan |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 6,926 | $96.15 | $666K | -3.4% | plan |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 16,595 | $95.34 | $1.6M | -7.5% | plan |
| Jun 1, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 2,602 | $94.64 | $246K | -1.2% | plan |
| Jun 1, 2026 | Ramasastry SairaD | ▼ Sale | 3,977 | $100 | $398K | -100% | plan |
| Apr 15, 2026 | Ramasastry SairaD | ▼ Sale | 2,000 | $96.9 | $194K | -100% | plan |
| Mar 16, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 4,732 | $91.98 | $435K | -36% | — |
| Mar 16, 2026 | Quan JoanneCHIEF MEDICAL OFFICER · O | ▼ Sale | 7,287 | $91.98 | $670K | -27.9% | — |
| Mar 16, 2026 | Radovich PeterPRESIDENT AND COO · O | ▼ Sale | 16,515 | $91.98 | $1.5M | -29.1% | — |
| Mar 16, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 40,985 | $91.98 | $3.8M | -17.4% | — |
| Mar 16, 2026 | Ramasastry SairaD | ▼ Sale | 2,000 | $90.76 | $182K | -100% | plan |
| Mar 16, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 7,287 | $91.98 | $670K | -12.8% | — |
| Feb 13, 2026 | Ramasastry SairaD | ▼ Sale | 2,000 | $102.09 | $204K | -100% | plan |
| Feb 2, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 968 | $103.3 | $100K | -17.7% | — |
| Feb 2, 2026 | Radovich PeterPRESIDENT AND COO · O | ▼ Sale | 2,631 | $103.3 | $272K | -11.3% | — |
| Feb 2, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 9,108 | $103.3 | $941K | -5.4% | — |
| Jan 26, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 842 | $96.19 | $81K | -18.5% | — |
| Jan 26, 2026 | Radovich PeterPRESIDENT AND COO · O | ▼ Sale | 3,143 | $96.19 | $302K | -11.9% | — |
| Jan 26, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 6,831 | $96.19 | $657K | -3.9% | — |
| Jan 26, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 1,053 | $96.19 | $101K | -2.4% | — |
| Jan 23, 2026 | Heron Patrick JD | ▲ Buy | 131,425 | $68.48 | $9.0M | +40.1% | indirect |
| Jan 22, 2026 | Howe JolandaSVP, GLOBAL CONTROLLER · O | ▼ Sale | 926 | $93.33 | $86K | -23.3% | — |
| Jan 22, 2026 | Quan JoanneCHIEF MEDICAL OFFICER · O | ▼ Sale | 1,822 | $93.33 | $170K | -12.4% | — |
| Jan 22, 2026 | Radovich PeterPRESIDENT AND COO · O | ▼ Sale | 2,382 | $93.33 | $222K | -10.3% | — |
| Jan 22, 2026 | Peetz ChristopherCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 7,098 | $93.33 | $662K | -4.2% | — |
| Jan 22, 2026 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 1,421 | $93.33 | $133K | -3.3% | — |
| Jan 20, 2026 | Quan JoanneCHIEF MEDICAL OFFICER · O | ▼ Sale | 6,911 | $90.27 | $624K | -37.9% | — |
| Jan 15, 2026 | Ramasastry SairaD | ▼ Sale | 2,000 | $90.99 | $182K | -100% | plan |
| Dec 22, 2025 | Ramasastry SairaD | ▼ Sale | 5,000 | $80 | $400K | -100% | plan |
| Dec 19, 2025 | GREY MICHAEL GD | ▼ Sale | 50,000 | $78 | $3.9M | -100% | plan |
| Dec 18, 2025 | Ramasastry SairaD | ▼ Sale | 2,000 | $69.73 | $139K | -100% | plan · 2 tranches |
| Dec 1, 2025 | GREY MICHAEL GD | ▼ Sale | 50,000 | $74 | $3.7M | -100% | plan |
| Nov 21, 2025 | GREY MICHAEL GD | ▼ Sale | 50,000 | $70 | $3.5M | -100% | plan |
| Sep 12, 2025 | BJERKHOLT ERICCHIEF FINANCIAL OFFICER · O | ▼ Sale | 9,578 | $76.01 | $728K | -19.3% | — |
| Sep 11, 2025 | Brege LauraD | ▼ Sale | 17,000 | $74.4 | $1.3M | -52% | 2 tranches |
| Sep 8, 2025 | Ramasastry SairaD | ▼ Sale | 17,000 | — | — | -100% | — |
Every $MIRM filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Mirum Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MIRM feed.